Loading clinical trials...
Loading clinical trials...
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Conditions
Interventions
octanorm 16.5%
Locations
24
United States
Octapharma Research Site
Birmingham, Alabama, United States
Octapharma Research Site
Irvine, California, United States
Octapharma Research Site
San Diego, California, United States
Octapharma Research Site
Centennial, Colorado, United States
Octapharma Research Site
Omaha, Nebraska, United States
Octapharma Research Site
Toledo, Ohio, United States
Start Date
March 1, 2014
Primary Completion Date
June 9, 2020
Completion Date
June 9, 2020
Last Updated
August 17, 2021
NCT03266627
NCT04197596
NCT02888535
NCT04354818
NCT00538915
NCT03492710
Lead Sponsor
Octapharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions